Related Experiment Video
Updated: Mar 20, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Cost-Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic
Johan Jendle1, Kirsten Nørgaard2,3, Elina Pimiä4
1School of Medicine, Örebro University, Örebro, Sweden.
Aims:
This study evaluated long-term cost-effectiveness of automated insulin delivery (AID) systems versus multiple daily injections (MDI) + CGM in children with type 1 diabetes (T1D), adults with T1D and insulin-treated individuals with type 2 diabetes (T2D) across Denmark, Finland, Norway and Sweden.
Materials And Methods:
Clinical outcomes and economic footprints were analysed for horizons up to 50 years from a healthcare system perspective using the IQVIA Core Diabetes Model. Five patient profiles were modelled: T1D paediatrics (T1D-Paed), T1D adults with high baseline HbA1c (T1D-Adult), real-world evidence in T1D adults with lower baseline HbA1c (T1D-AdultRWE), T2D adults (T2D-Adult) and older T2D adults (T2D-Elder). Costs were inflated to July 2024, with 3% annual discounting. Sensitivity analyses explored scenarios varying time horizons and HbA1c effect sizes and inclusion of hypoglycaemia rates.
Results:
AID systems were estimated to lead to a reduction in diabetes-related complications in all groups, most notably in the T1D-Adult group (318 vs. 542 complications per 100 individuals). Improvements translated into lifetime cost savings (€1435 to €26 259), increased life expectancy (LE) and more quality-adjusted life years (QALYs). Incremental cost-effectiveness ratios (ICERs) remained below willingness-to-pay thresholds in all countries (from €14 695/QALY for T1D-Adult in Finland to €56 711/QALY for T1D-AdultRWE in Denmark), confirming AID is cost-effective across all groups in the Nordic region.
Conclusions:
AID therapy consistently projected reduced diabetes-related complications while remaining cost-effective across a broad spectrum of diabetes patient profiles in the Nordic region. These findings strengthen the case towards widespread integration of AID technology into national diabetes care frameworks.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

